Enliven Therapeutics Inc. Common Stock (ELVN)
Stock · NASDAQ · Health Care
$37.35as of 10/16/2026
Price chart
Active signals
Resistance level
$40.57
Industry
Biotechnology: Pharmaceutical Preparations
ELVN Signal Track Record
How signals performed across all stocks →What ELVN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +2.8% | 56% | September 16, 2026 |
| Bollinger Band Breakout | 25 | +1.1% | 56% | July 21, 2026 |
| Bollinger Band Breakdown | 20 | +6.8% | 75% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -2.3% | 31% | October 8, 2026 |
| Any 20-session window (baseline) | +0.9% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ELVN
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal gro…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 67
- Website
- www.enliventherapeutics.com/
Fundamentals
- 1-day range
- $38.49$40.28
- Market cap
- $3.67B
- P/E (trailing)
- —
- P/E (forward)
- -16.71
- EPS (trailing)
- $-1.67
- Dividend yield
- —
- Beta
- 0.56
- Avg. volume
- 1.15M
52-week range
$14.79$62.32
Next earnings: November 11, 2026 · EPS estimate $-0.46confirmed
Forecasts
13 analyst ratings
Buy 95%
Hold 5%
Sell 0%
1-year price forecast
High
$82
+119.5%
Median
$75
+100.8%
Low
$64
+71.4%
Enliven Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- GMABGenmab A/S ADS$37▼ 2.17%Market cap $3.83BP/E 26.41$1,512$2,369
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| GMAB Genmab A/S ADS | $3.83B | 26.41 | $37 | ▼ 2.17% | $1,512$2,369 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML StrategyYahoo · 10/10/2026
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialYahoo · 10/7/2026
- Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaYahoo · 10/6/2026
- This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga · 10/2/2026
- This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 10/2/2026
- Morgan Stanley Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $70Benzinga · 10/2/2026
- JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75Benzinga · 10/1/2026
- Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →Acquired
27.0K
Disposed
35.0K
- Garland J. Scott · October 1, 2026 · Option Exercise13.0K @ $15.47
- Garland J. Scott · October 1, 2026 · Sale13.0K @ $46.67
- Hohl Benjamin · September 17, 2026 · Option Exercise4.0K @ $14.85
- Hohl Benjamin · September 17, 2026 · Sale289 @ $51.49
- Hohl Benjamin · September 17, 2026 · Sale2.2K @ $50.72
- Hohl Benjamin · September 17, 2026 · Sale3.5K @ $50.03
- Collins Helen Louise · September 17, 2026 · Option Exercise5.0K @ $2.48
- Collins Helen Louise · September 17, 2026 · Sale240 @ $51.48
- Collins Helen Louise · September 17, 2026 · Sale1.8K @ $50.71
- Collins Helen Louise · September 17, 2026 · Sale2.9K @ $50.03
- Hohl Benjamin · August 17, 2026 · Sale1.4K @ $59.35
- Hohl Benjamin · August 17, 2026 · Sale4.6K @ $58.35
- Collins Helen Louise · August 17, 2026 · Option Exercise5.0K @ $2.48
- Collins Helen Louise · August 17, 2026 · Sale1.1K @ $59.35
- Collins Helen Louise · August 17, 2026 · Sale3.9K @ $58.37
Institutional Ownership
March 31, 2026
- Total shares held
- 61.77M
- Total value held
- $2.40B
- Institutional holders
- 170
Top holders this quarter
- Unknown7.96M
- Unknown6.83M
- Unknown5.07M
- Unknown3.68M
- Unknown3.27M
- Unknown3.25M
- Unknown2.32M
- Unknown1.87M
- Unknown1.86M
- Unknown1.73M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Enliven's ENABLE-2 Trial Design Sparks New Questions
Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.
Enliven's ENABLE-2 Trial Design Sparks New Questions. Enliven Therapeutics has clarified the design of its ENABLE-2 Phase 3 trial for relcobatinib in chronic myeloid leukemia, following questions raised by the trial’s structure. The company also confirmed FDA alignment on the study, while a separate patent dispute involving Halozyme and Merck has kept the leukemia treatment landscape in focus. These developments highlight the regulatory and strategic challenges Enliven faces as it moves toward clinical milestones.